Minkyu Hur
Overview
Explore the profile of Minkyu Hur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee K, Koo H, Kim Y, Kim D, Son E, Yang H, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33142709
We aimed to evaluate the preclinical efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb), against glioblastoma (GBM) tumors using patient-derived xenograft (PDX) models. A total...
2.
Lee H, Son E, Lee K, Lee Y, Kim Y, Lee J, et al.
Int J Mol Sci
. 2019 Nov;
20(23).
PMID: 31771279
Epidermal growth factor receptor (EGFR)-targeted monoclonal antibodies, including cetuximab and panitumumab, are used to treat metastatic colorectal cancer (mCRC). However, this treatment is only effective for a small subset of...
3.
Park J, Jin M, Hur M, Nam A, Bang J, Won J, et al.
Gastric Cancer
. 2019 Mar;
22(5):932-940.
PMID: 30815759
Background: EGFR overexpression in gastric cancer (GC) has been reported in about 30% of patients. However, the anti-EGFR antibodies cetuximab and panitumumab have failed to improve overall survival of GC...
4.
Lim Y, Yoo J, Kim M, Hur M, Lee E, Hur H, et al.
Mol Cancer Ther
. 2015 Nov;
15(2):251-63.
PMID: 26586721
The EGFR-targeted monoclonal antibodies are a valid therapeutic strategy for patients with metastatic colorectal cancer (mCRC). However, only a small subset of mCRC patients has therapeutic benefits and there are...
5.
Jung E, Hur M, Kim Y, Lee G, Kim J, Kim I, et al.
J Pharmacol Exp Ther
. 2009 Sep;
331(3):1005-13.
PMID: 19741152
T cells play a pivotal role in the initiation and progression of multiple sclerosis. We have found that 1,4-aryl-2-mercaptoimidazole (KRM-III) inhibited T-cell antigen receptor- and phorbol myristate acetate/ionomycin-induced activation of...